.German TTP-Registry (Thrombotic Thrombocytopenic Purpura)

German TTP- Registry- Prospective Cohort of Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP): Pathophysiology, Diagnosis, Treatment and Follow-Up

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05389007

Acronym

RGTTP

Enrollment

156

Registered

2022-05-24

Start date

2016-07-08

Completion date

Unknown

Last updated

2022-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombotic Thrombocytopenic Purpura

Brief summary

Open, multi-center, observational, prospective cohort study, only disease-indicated treatment, in patients with clinically diagnosed acquired and congenital TTP regardless of gender, ethnicity, and comorbidities, over the age of 18 for 1.) prospective investigation of patients with TTP in an acute bout and during long-term follow and 2.) assessment of prevalence, course of disease, success of therapy, possible triggers for relapses and possibilities for better diagnosis and prognosis.

Detailed description

1.) Identification of predictive markers for morbidity and mortality in acute TTP and in TTP relapses using a prospective long-term registry and 2.) Investigation of the pathophysiological processes in acute bouts and in remission by recording the clinical symptoms and diagnostics for a better understanding of the course of the disease, optimization of diagnostic procedures and their correlation with the clinical course, recording of therapy response of all therapeutic options in acute bouts, observation of current treatment options to evaluate outcome and prognostic markers and recording of clinical and laboratory chemical data during follow-up to assess long-term morbidity.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with clinically diagnosed acquired and congenital TTP regardless of gender, ethnicity, and comorbidities, over the age of 18. * Patients incapable to give consent, who are accompanied by a legal representative during admission to the study, after the written informed consent of the legal representative. * Written informed consent of the patient.

Exclusion criteria

* Patients who are not able to understand the German or English language. * Patients who are permanently unable to communicate and who are not accompanied by a legal representative.

Design outcomes

Primary

Measure	Time frame	Description
Predictive markers for morbidity and mortality	3 years	Identification of predictive markers for morbidity and mortality in acute TTP and in TTP relapses using a prospective long-term registry

Countries

Germany

Contacts

Primary ContactCharis v. Auer-Wegener

charis.von-auer@unimedizin-mainz.de

Outcome results